Nature Biotechnology Прикладная микробиология и биотехнология

A comprehensive analysis of CBER experience with AAV gene therapy IND submissions

Sojin Bing, Takele Argaw, Megha Kaushal, Ronit Mazor
Springer Nature · 2026-11-12 · DOI 10.1038/s41587-026-03378-9
⬢ Цитируемость: 0 Crossref

Аннотация

Nature Biotechnology, Published online: 12 November 2026; doi:10.1038/s41587-026-03378-9 An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in adeno-associated virus (AAV) development over three decades and highlights common reasons for regulatory holds that should be considered for successful product development.

Читать у издателя →